[go: up one dir, main page]

PE20091107A1 - SOLID FUNCTIONALIZED POLYMER NANOPARTICLES INCLUDING EPOTILONES - Google Patents

SOLID FUNCTIONALIZED POLYMER NANOPARTICLES INCLUDING EPOTILONES

Info

Publication number
PE20091107A1
PE20091107A1 PE2008002025A PE2008002025A PE20091107A1 PE 20091107 A1 PE20091107 A1 PE 20091107A1 PE 2008002025 A PE2008002025 A PE 2008002025A PE 2008002025 A PE2008002025 A PE 2008002025A PE 20091107 A1 PE20091107 A1 PE 20091107A1
Authority
PE
Peru
Prior art keywords
diona
dihydroxy
prop
tetramethyl
epotilones
Prior art date
Application number
PE2008002025A
Other languages
Spanish (es)
Inventor
Katrin Fischer
Sascha General
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091107A1 publication Critical patent/PE20091107A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A NANOPARTICULAS POLIMERICAS CON POTENCIAL SUPERFICIAL CATIONICO QUE COMPRENDEN: A) UN POLIMERO CATIONICO TAL COMO UN POLIACRILATO MODIFICADO CON CATIONES POLI(N,N-DIMETILAMINOETILMETACRILATO) O POLI(N,N-DIMETILAMINOPROPILMETACRILAMIDA); B) UN POLIMERO POCO SOLUBLE EN AGUA TAL COMO UN POLIESTER, ACIDO ALGINICO, ACIDO HIALURONICO, POLIURETANOS, ENTRE OTROS; C) AGENTES DE DIAGNOSTICO Y EPOTILONAS TALES COMO (4S,7R,8S,9S,13E/Z,16S)-4,8-DIHIDROXI-16-(2-METILBENZOXAZOL-5-IL)-1-OXA-5,5,9,13-TETRAMETIL-7-(PROP-2-EN-1-IL)CICLOHEXADEC-13-EN-2,6-DIONA, (4S,7R,8S,9S,13E/Z,16S)-4,8-DIHIDROXI-16-(2-METILBENZOTIAZOL-5-IL)-1-OXA-5,5,9,13-TETRAMETIL-7-(PROP-2-EN-1-IL)-CICLOHEXADEC-13-EN-2,6-DIONA, (1S/R,3S,7S,10R,11S,12S,16R/S)-7,11-DIHIDROXI-10-(PROP-2-EN-1-IL)-3-(2-METILBENZOTIAZOL-5-IL)-8,8,12,16-TETRAMETIL-4,17-DIOXABICICLO[14,1,0]HEPTADECAN-5,9-DIONA, ENTRE OTROS. DONDE LA SUPERFICIE DE LAS NANOPARTICULAS HA SIDO SOMETIDA A UNA MODIFICACION ELECTROSTATICA CON UN AGENTE MODIFICADOR DE SUPERFICIE QUE CONTIENE UNA ESTRUCTURA CAPAZ DE RECONOCER EL BLANCO TAL COMO UN ANTICUERPO, UN POLIPEPTIDO, UNA MOLECULA DE ADN, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHAS NANOPARTICULAS Y ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASICASREFERS TO POLYMERIC NANOPARTICLES WITH CATIONIC SURFACE POTENTIAL, INCLUDING: A) A CATIONIC POLYMER SUCH AS A POLY (N, N-DIMETHYLAMINEETHYL METHACRYLATE) OR POLY (N, N, N-DIMETHYLAMINOETHYLMETHYLAMIDE) POLYMETHYL-DIMETILAMIDE; B) A POLYMER POORLY SOLUBLE IN WATER SUCH AS A POLYESTER, ALGINIC ACID, HYALURONIC ACID, POLYURETHANES, AMONG OTHERS; C) DIAGNOSTIC AGENTS AND EPOTILONES SUCH AS (4S, 7R, 8S, 9S, 13E / Z, 16S) -4,8-DIHYDROXY-16- (2-METHYLBENZOXAZOLE-5-IL) -1-OXA-5.5 , 9,13-TETRAMETHYL-7- (PROP-2-EN-1-IL) CYCLOHEXADEC-13-EN-2,6-DIONA, (4S, 7R, 8S, 9S, 13E / Z, 16S) -4, 8-DIHYDROXY-16- (2-METHYLBENZOTHIAZOL-5-IL) -1-OXA-5,5,9,13-TETRAMETHYL-7- (PROP-2-EN-1-IL) -CYCLOHEXADEC-13-EN- 2,6-DIONA, (1S / R, 3S, 7S, 10R, 11S, 12S, 16R / S) -7,11-DIHYDROXY-10- (PROP-2-EN-1-IL) -3- (2 -METHYLBENZOTHIAZOL-5-IL) -8,8,12,16-TETRAMETHYL-4,17-DIOXABICYCLO [14,1,0] HEPTADECAN-5,9-DIONA, AMONG OTHERS. WHERE THE SURFACE OF THE NANOPARTICLES HAS BEEN SUBJECTED TO AN ELECTROSTATIC MODIFICATION WITH A SURFACE MODIFYING AGENT THAT CONTAINS A STRUCTURE CAPABLE OF RECOGNIZING THE TARGET SUCH AS AN ANTIBODY, A POLYPEPTIDE, A MOLECULE OR DNA, BETWEEN. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING SUCH NANOPARTICLES AND IS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES

PE2008002025A 2007-12-10 2008-12-09 SOLID FUNCTIONALIZED POLYMER NANOPARTICLES INCLUDING EPOTILONES PE20091107A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007059752A DE102007059752A1 (en) 2007-12-10 2007-12-10 Functionalized solid polymer nanoparticles containing epothilones

Publications (1)

Publication Number Publication Date
PE20091107A1 true PE20091107A1 (en) 2009-08-29

Family

ID=40409013

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002025A PE20091107A1 (en) 2007-12-10 2008-12-09 SOLID FUNCTIONALIZED POLYMER NANOPARTICLES INCLUDING EPOTILONES

Country Status (7)

Country Link
AR (1) AR069638A1 (en)
DE (1) DE102007059752A1 (en)
PA (1) PA8806901A1 (en)
PE (1) PE20091107A1 (en)
TW (1) TW200932220A (en)
UY (1) UY31521A1 (en)
WO (1) WO2009074274A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2462090T5 (en) 2008-06-16 2017-07-12 Pfizer Inc. Polymeric nanoparticles loaded with drug and manufacturing processes and use thereof
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
ES2721850T3 (en) 2008-06-16 2019-08-05 Pfizer Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of manufacturing and using them
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (en) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド Long-circulating nanoparticles for sustained release of therapeutic agents
CN102361636A (en) * 2009-03-03 2012-02-22 公立大学法人横浜市立大学 Amino acid-conjugated cyanoacrylate polymer particles
ES2721898T3 (en) 2009-12-11 2019-08-06 Pfizer Stable formulations to lyophilize therapeutic particles
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011084521A2 (en) * 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2012026608A1 (en) * 2010-08-24 2012-03-01 Canon Kabushiki Kaisha Polymeric particle and hydrophilic dye having a sulfonate group encapsulated within the particle
DK2895156T3 (en) 2012-09-17 2019-07-15 Pfizer Method for the preparation of therapeutic nanoparticles
JP6564369B2 (en) 2013-12-09 2019-08-21 デュレクト コーポレイション Pharmaceutically active agent conjugates, polymer conjugates, and compositions and methods involving them
SI3116547T1 (en) 2014-03-14 2019-08-30 Pfizer, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2015181346A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
DE102017100317A1 (en) 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostructured carrier system for gene delivery
CN115078292B (en) * 2021-03-10 2025-02-11 北京大学 A kind of water-based supramolecular adhesion material and preparation method thereof
CN119768461A (en) * 2022-08-22 2025-04-04 爱克发-格法特公司 Near infrared and red light absorbing composite resin particles

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262030A (en) 1882-08-01 Wash-stand
US252028A (en) 1882-01-10 Alonzo s
US258286A (en) 1882-05-23 Fruit-drier
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
CA2032169A1 (en) * 1989-05-04 1990-11-05 Steven Kornguth Method for localization and treatment of tumors and complexes therefor
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
FR2684103B1 (en) 1991-11-22 1994-09-02 Centre Nat Rech Scient NOVEL COMPOUNDS WITH GUANIDIC STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
JP4183099B2 (en) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） Epothilones C and D, production methods and compositions
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19728914A1 (en) 1997-07-07 1999-01-14 Basf Ag Metallic colored polyamides
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
WO1999007692A2 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO1999018934A1 (en) * 1997-10-09 1999-04-22 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
DE19820599A1 (en) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh New epothilone derivatives useful as pharmaceuticals and in plant protection
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
SE517641C2 (en) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Process for making a material layer with barrier tabs and a surface layer with such barrier tabs
JP2000095758A (en) 1998-09-18 2000-04-04 Schering Ag Near-infrared, fluorescent contrast medium, and its production
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
DE19908763A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
DE19908760A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
SK11852001A3 (en) 1999-02-18 2002-04-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19907588A1 (en) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis
IL144590A0 (en) 1999-03-29 2002-05-23 Bristol Myers Squibb Co A process for the preparation of epothilone derivatives
AR023792A1 (en) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag DERIVATIVES 6-ALQUENILO- AND 6-ALQUINILO-EPOTILONA, THE PROCEDURES TO PREPARE THEM AND THEIR USE IN PHARMACEUTICAL PRODUCTS
CA2425620A1 (en) 1999-10-08 2001-04-19 The Scripps Research Institute 13-alkyl epothilone derivatives
EP1259490A2 (en) 2000-03-01 2002-11-27 Sloan Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (en) 2000-04-19 2001-10-25 Schering Ag New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
US20020137152A1 (en) 2000-07-25 2002-09-26 Daniel Santi Fermentation process for epothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2425828A1 (en) 2000-10-13 2002-04-18 The University Of Mississippi Synthesis of epothilones and related analogs
ATE349412T1 (en) 2000-10-16 2007-01-15 R & D Biopharmaceuticals EPOTHILONE SYNTHESIS COMPONENTS I: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF EPOTHILONES AND EPOTHILONE DERIVATIVES
WO2002080846A2 (en) 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
DE102005041860A1 (en) * 2005-09-02 2007-03-08 Schering Ag Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
JP2009539793A (en) * 2006-06-08 2009-11-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications

Also Published As

Publication number Publication date
UY31521A1 (en) 2009-08-03
TW200932220A (en) 2009-08-01
DE102007059752A1 (en) 2009-06-18
WO2009074274A1 (en) 2009-06-18
PA8806901A1 (en) 2009-07-23
AR069638A1 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
PE20091107A1 (en) SOLID FUNCTIONALIZED POLYMER NANOPARTICLES INCLUDING EPOTILONES
Murugesan et al. Chitosan‐based nanocomposites for medical applications
Gowda et al. Stimuli-responsive microneedles as a transdermal drug delivery system: a demand-supply strategy
Ayoubi‐Joshaghani et al. Potential applications of advanced nano/hydrogels in biomedicine: static, dynamic, multi‐stage, and bioinspired
Zahid et al. Leveraging the advancements in functional biomaterials and scaffold fabrication technologies for chronic wound healing applications
Doraiswamy et al. Two photon induced polymerization of organic–inorganic hybrid biomaterials for microstructured medical devices
Ma et al. Mesoporous silica as micro/nano-carrier: From passive to active cargo delivery, a mini review
Razatos et al. Force measurements between bacteria and poly (ethylene glycol)-coated surfaces
Korkmaz et al. Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays
Hou et al. Microtopographic patterns affect Escherichia coli biofilm formation on poly (dimethylsiloxane) surfaces
EP3548135B1 (en) Core-shell microneedle devices and uses thereof
AR117389A2 (en) COMPOSITIONS OF FENYLALANINAMONIACOLIASA OF PROCARIONTES AND USE OF ITS COMPOSITIONS IN METHODS TO TREAT CANCER
BRPI0905752A2 (en) "Human tear lipocalin mutein (htlc), nucleic acid molecule, host cell, pharmaceutical composition, method for the production of a human tear lipocalin mutein, method of treating a disease or disorder and use of a lipocalin matein of human tear "
Massaro et al. Multifunctional carrier based on halloysite/laponite hybrid hydrogel for kartogenin delivery
WO2010123945A3 (en) Silk fibroin hydrogels and uses thereof
Yang et al. Intra‐articular injection of nanomaterials for the treatment of osteoarthritis: from lubrication function restoration to cell and gene therapy
Barthes et al. Stretch-induced biodegradation of polyelectrolyte multilayer films for drug release
Chen et al. Robust, flexible, and bioadhesive free-standing films for the co-delivery of antibiotics and growth factors
Majcher et al. Applications of hydrogels
Seo et al. Diatom microbubbler for active biofilm removal in confined spaces
WO2008085556A3 (en) Surfactant-free nanoparticles for drug delivery
Zhou et al. Dynamic and wearable electro-responsive hydrogel with robust mechanical properties for drug release
Pepelanova Tunable hydrogels: introduction to the world of smart materials for biomedical applications
Phoungtawee et al. Polymers with hemiaminal ether linkages for pH-responsive antibacterial materials
Yu et al. β-Lactamase responsive supramolecular hydrogels with host–guest self-healing capability

Legal Events

Date Code Title Description
FA Abandonment or withdrawal